home / stock / sls / sls news

SLS News and Press, SELLAS Life Sciences Group Inc. From 06/14/23

Stock Information
Company Name: SELLAS Life Sciences Group Inc.
Stock Symbol: SLS
Market: NASDAQ
Website: sellaslifesciences.com
Menu
SLS SLS Quote SLS Short SLS News SLS Articles SLS Message Board
Get SLS Alerts

News, Short Squeeze, Breakout and More Instantly...
SLS - Solaris Reports Significant New Porphyry Discovery in First Hole at Patrimonio, Second and Third Holes Underway and Additional Rigs Being Mobilized

VANCOUVER, British Columbia, June 14, 2023 (GLOBE NEWSWIRE) -- Solaris Resources Inc . (TSX: SLS; OTCQB: SLSSF) (“Solaris” or the “Company”) is pleased to announce the discovery of a significant new porphyry deposit in the first reconnaissance drill hole at the Pat...
SLS - SELLAS to Participate in Maxim Group Healthcare Virtual Conference

NEW YORK, June 13, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announce...

SLS - Solaris Reports Highest Grades to Date in Second Porphyry Centre Outside Resource at Warintza East, with 301m of 0.65% CuEq from Surface Ending in 31m of 0.76% CuEq

VANCOUVER, British Columbia, June 01, 2023 (GLOBE NEWSWIRE) -- Solaris Resources Inc . (TSX: SLS; OTCQB: SLSSF) (“Solaris” or the “Company”) is pleased to announce assay results confirming the discovery of a second porphyry center featuring the highest grades to da...

SLS - SELLAS Life Sciences to Present Phase 3 REGAL Trial in Progress Poster at 2023 ASCO Annual Meeting

NEW YORK, May 25, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced...
SLS - SELLAS Life Sciences to Host Virtual Expert Panel Discussion on GFH009 in Acute Myeloid Leukemia

NEW YORK, May 16, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today a...

SLS - SELLAS Life Sciences GAAP EPS of -$0.47 misses by $0.18

2023-05-11 17:05:31 ET SELLAS Life Sciences press release ( NASDAQ: SLS ): Q1 GAAP EPS of -$0.47 misses by $0.18 . As of March 31, 2023, cash and cash equivalents totaled approximately $23.9 million. For further details see: SELLAS Life Sciences GAAP EPS of -...

SLS - SELLAS Life Sciences Provides Business Update and Reports First Quarter 2023 Financial Results

Phase 1 Study of Novel, Highly Selective CDK9 Inhibitor GFH009 Successfully Completed for Patients with Acute Myeloid Leukemia; 94% of Patients Enrolled to Date Alive and Durable Remission in Patient with Acute Myeloid Leukemia > 6 months Phase 3 REGAL Study of Galinpepimut-S in Pati...
SLS - SELLAS Announces Positive Topline Data from GFH009 Phase 1 Dose-Escalation Trial in Acute Myeloid Leukemia Cohort Supporting Advancement to Phase 2 Clinical Study

- 72 Acute Myeloid Leukemia and Lymphoma High-Risk Advanced Patients Enrolled: 94% Alive at Last Assessment Indicating Favorable Survival Benefit - - Long-Term Complete Remission and Significant Bone Marrow Blast Reductions in Acute Myeloid Leukemia: Durable Complete Remission with No Min...

SLS - Solaris Confirms Discovery of Second Porphyry Center with Stronger Mineralization, Higher Grade Growth Potential at Warintza East

VANCOUVER, British Columbia, May 02, 2023 (GLOBE NEWSWIRE) -- Solaris Resources Inc . (TSX: SLS; OTCQB: SLSSF) (“Solaris” or the “Company”) is pleased to confirm the discovery of a second and more intensely mineralized porphyry center 350m south of the original dis...

SLS - SELLAS Life Sciences Announces Abstract Accepted for Presentation at ASCO 2023 Annual Meeting

NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today...
Previous 10 Next 10